The impact of immunohistochemistry on the classification of lung tumors

References

• Travis W, Brambilla E, Burke A, et al. WHO Classification of tumours of the lung, pleura, thymus and heart. In: Bosman F, Jaffe E, Lakhani S, et al., editors. World Health Organization Classification of Tumours. Lyon: IARC Press; 2015.
   Google Scholar
• Travis W, Brambilla E, Muller-Hermelink H, et al. Tumours of the lung, pleura, thymus and heart, (ed. Cancer, IAfRo). IARC Press, Lyon. 2004.
   Google Scholar
• Travis W, Colby T, Corrin B, et al. Hystological typing of lung and pleural tumours (ed. Organization, WH). Berlin Heidelberg New York: Springer Verlag; 1999.
   Google Scholar
• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Arch Pathol Lab Med. 2013;137(5):668–684.
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6:244–285.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Barbareschi M, Cavazza A, et al. Large cell carcinoma of the lung: a tumor in search of an author. A clinically oriented critical reappraisal. Lung Cancer. 2015;87(3):226–231.
   PubMed Web of Science ®Google Scholar
• Rossi G, Graziano P, Leone A, et al. The role of molecular analyses in the diagnosis and treatment of non-small-cell lung carcinomas. Semin Diagn Pathol. 2013;30(4):298–312.
   PubMed Web of Science ®Google Scholar
• Rossi G, Papotti M, Barbareschi M, et al. Morphology and a limited number of immunohistochemical markers may efficiently subtype non-small-cell lung cancer. J Clin Oncol. 2009;27(28):e141–e142. author reply e143–144.
   PubMed Web of Science ®Google Scholar
• Rossi G, Pelosi G, Graziano P, et al. A reevaluation of the clinical significance of histological subtyping of non–small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol. 2009;17(3):206–218.
   PubMed Web of Science ®Google Scholar
• Sholl LM. Large-cell carcinoma of the lung: a diagnostic category redefined by immunohistochemistry and genomics. Curr Opin Pulm Med. 2014;20(4):324–331.
   PubMed Web of Science ®Google Scholar
• Weissferdt A. Large cell carcinoma of lung: on the verge of extinction? Semin Diagn Pathol. 2014;31:278–288.
   PubMed Web of Science ®Google Scholar
• Edwards CW. Pulmonary adenocarcinoma: review of 106 cases and proposed new classification. J Clin Pathol. 1987;40(2):125–135.
   PubMed Web of Science ®Google Scholar
• Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol. 2009;22(5):709–717.
   PubMed Web of Science ®Google Scholar
• Pardo J, Martinez-Peñuela AM, Sola JJ, et al. Large cell carcinoma of the lung: an endangered species? Appl Immunohistochem Mol Morphol. 2009;17(5):383–392.
   PubMedGoogle Scholar
• Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011;117(15):3416–3423.
   PubMed Web of Science ®Google Scholar
• Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011;24(10):1348–1359.
   PubMed Web of Science ®Google Scholar
• Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol. 2011;6(3):451–458.
   PubMed Web of Science ®Google Scholar
• Sigel CS, Moreira AL, Travis WD, et al. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol. 2011;6(11):1849–1856.
   PubMed Web of Science ®Google Scholar
• Sigel CS, Rudomina DE, Sima CS, et al. Predicting pulmonary adenocarcinoma outcome based on a cytology grading system. Cancer Cytopathol. 2012;120(1):35–43.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Fabbri A, Papotti M, et al. Dissecting pulmonary large-cell carcinoma by targeted next generation sequencing of several cancer genes pushes genotypic-phenotypic correlations to emerge. J Thorac Oncol. 2015;10(11):1560–1569.
   PubMed Web of Science ®Google Scholar
• Lewis DR, Check DP, Caporaso NE, et al. US lung cancer trends by histologic type. Cancer. 2014;120(18):2883–2892.
   PubMed Web of Science ®Google Scholar
• Byers T, Wender RC, Jemal A, et al. The American Cancer Society challenge goal to reduce US cancer mortality by 50% between 1990 and 2015: results and reflections. CA Cancer J Clin. 2016;66(5):359–369.
   PubMed Web of Science ®Google Scholar
• Van Der Steen N, Giovannetti E, Pauwels P, et al. cMET exon 14 skipping: from the structure to the clinic. J Thorac Oncol. 2016;11(9):1423–1432.
   PubMed Web of Science ®Google Scholar
• Gazdar AF, Hirsch FR, Minna JD. From mice to men and back: an assessment of preclinical model systems for the study of lung cancers. J Thorac Oncol. 2016;11(3):287–299.
   PubMed Web of Science ®Google Scholar
• Suda K, Murakami I, Yu H, et al. Heterogeneity of EGFR aberrations and correlation with histological morphologies: analyses of therapy naive isogenic lung cancer lesions with EGFR mutation. J Thorac Oncol. pii: S1556-0864(16)30492-0. doi:10.1016/j.jtho.2016.05.017.
   Web of Science ®Google Scholar
• Pelosi G, Gasparini P, Conte D, et al. Synergistic activation upon MET and ALK coamplification sustains targeted therapy in sarcomatoid carcinoma, a deadly subtype of lung cancer. J Thorac Oncol. 2016;11(5):718–728.
   PubMed Web of Science ®Google Scholar
• Pastorino U, Boffi R, Marchiano A, et al. Stopping smoking reduces mortality in low-dose computed tomography screening participants. J Thorac Oncol. 2016;11(5):693–699.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Pellegrinelli A, Fabbri A, et al. Deciphering intra-tumor heterogeneity of lung adenocarcinoma confirms that dominant, branching, and private gene mutations occur within individual tumor nodules. Virchows Arch. 2016;468(6):651–662.
   PubMed Web of Science ®Google Scholar
• Hu J, Boeri M, Sozzi G, et al. Gene signatures stratify computed tomography screening detected lung cancer in high-risk populations. EBioMedicine. 2015;2(8):829–838.
   Web of Science ®Google Scholar
• Infante M, Sestini S, Galeone C, et al. Lung cancer screening with low-dose spiral computed tomography: evidence from a pooled analysis of two Italian randomized trials. Eur J Cancer Prev. 2016. [Epub ahead of print].
   PubMedGoogle Scholar
• Silva M, Galeone C, Sverzellati N, et al. Screening with low-dose computed tomography does not improve survival of small cell lung cancer. J Thorac Oncol. 2016;11(2):187–193.
   PubMed Web of Science ®Google Scholar
• Tsao AS, Scagliotti GV, Bunn PA Jr, et al. Scientific advances in lung cancer 2015. J Thorac Oncol. 2016;11(5):613–638.
   PubMed Web of Science ®Google Scholar
• Bunn PA Jr, Minna JD, Augustyn A, et al. Small cell lung cancer: can recent advances in biology and molecular biology be translated into improved outcomes? J Thorac Oncol. 2016;11(4):453–474.
   PubMed Web of Science ®Google Scholar
• Tan DS, Yom SS, Tsao MS, et al. The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation positive non-small cell lung cancer: status in 2016. J Thorac Oncol. 2016;11(7):946–963.
   PubMed Web of Science ®Google Scholar
• Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011;8(3):184–187.
   PubMed Web of Science ®Google Scholar
• Cressman S, Browman GP, Hoch JS, et al. A time-trend economic analysis of cancer drug trials. Oncologist. 2015;20(7):729–736.
   PubMed Web of Science ®Google Scholar
• Chilosi M, Murer B. Mixed adenocarcinomas of the lung: place in new proposals in classification, mandatory for target therapy. Arch Pathol Lab Med. 2010;134(1):55–65.
   PubMed Web of Science ®Google Scholar
• Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med. 2008;132(3):384–396.
   PubMed Web of Science ®Google Scholar
• Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma. J Clin Oncol. 2009;27(12):2030–2037.
   PubMed Web of Science ®Google Scholar
• Pelosi G. The new taxonomy of lung adenocarcinoma stemming from a multidisciplinary integrated approach: novel pathology concepts and perspectives. J Thorac Oncol. 2011;6(2):241–243.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Sonzogni A, Viale G. The classification of lung carcinoma: time to change the morphology-based approach? Int J Surg Pathol. 2010;18(3):161–172.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Fraggetta F, Pasini F, et al. Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell lung carcinomas of the lung. Am J Surg Pathol. 2001;25:363–372.
   PubMed Web of Science ®Google Scholar
• Wang BY, Gil J, Kaufman D, et al. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum Pathol. 2002;33(9):921–926.
   PubMed Web of Science ®Google Scholar
• Yatabe Y, Mitsudomi T, Takahashi T. TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol. 2002;26(6):767–773.
   PubMed Web of Science ®Google Scholar
• Bishop JA, Teruya-Feldstein J, Westra WH, et al. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012;25(3):405–415.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Fabbri A, Bianchi F, et al. DeltaNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol. 2012;7(2):281–290.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Rossi G, Cavazza A, et al. DeltaNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization. Int J Surg Pathol. 2013;21(3):229–239.
   PubMed Web of Science ®Google Scholar
• Marchevsky AM, Wick MR. Diagnostic difficulties with the diagnosis of small cell carcinoma of the lung. Semin Diagn Pathol. 2015;32(6):480–488.
   PubMed Web of Science ®Google Scholar
• Wick MR, Marchevsky AM. Neuroendocrine neoplasms of the lung: concepts and terminology. Semin Diagn Pathol. 2015;32(6):445–455.
   PubMed Web of Science ®Google Scholar
• Lindskog C, Edlund K, Mattsson JS, et al. Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use? Expert Rev Mol Diagn. 2015;15(4):471–490.
   PubMed Web of Science ®Google Scholar
• Rossi G, Mengoli MC, Cavazza A, et al. Large cell carcinoma of the lung: clinically oriented classification integrating immunohistochemistry and molecular biology. Virchows Arch. 2014;464(1):61–68.
   PubMed Web of Science ®Google Scholar
• Smith BR. Therapeutic pathology: time to move beyond diagnostics. Hum Pathol. 2008;39(12):1725–1727.
   PubMed Web of Science ®Google Scholar
• Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer. 1995;75(1 Suppl):191–202.
   PubMed Web of Science ®Google Scholar
• Ellis L, Fox J, Peake MD, et al. Lung cancer in young women remains rare. Lung Cancer. 2010;67(1):124–125.
   PubMed Web of Science ®Google Scholar
• Colby T, Koss M, Travis W. Tumors of the lower respiratory tract. Washington (DC): Armed Forces Institute of Pathology; 1995.
   Google Scholar
• Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175–180.
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139.
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304(5676):1497–1500.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, Von Pawel J,, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–3551.
   PubMed Web of Science ®Google Scholar
• Puig de la Bellacasa R, Karachaliou N, Estrada-Tejedor R, et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res. 2013;2(2):72–86.
   PubMedGoogle Scholar
• Janne PA, Shaw AT, Camidge DR, et al. Combined pan-HER and ALK/ROS1/MET Inhibition with dacomitinib and crizotinib in advanced non-small cell lung cancer: results of a phase I study. J Thorac Oncol. 2016;11(5):737–747.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Crizotinib: a review of its use in the treatment of anaplastic lymphoma kinase-positive, advanced non-small cell lung cancer. Drugs. 2013;73(18):2031–2051.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371(21):1963–1971.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Berry J, Roxas M, et al. Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer. 2015;89(1):76–79.
   PubMed Web of Science ®Google Scholar
• Platt A, Morten J, Ji Q, et al. A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer. 2015;15:171.
   PubMed Web of Science ®Google Scholar
• van der Heijden EH, Casal RF, Trisolini R, et al. Guideline for the acquisition and preparation of conventional and endobronchial ultrasound-guided transbronchial needle aspiration specimens for the diagnosis and molecular testing of patients with known or suspected lung cancer. Respiration. 2014;88(6):500–517.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, Wynes MW, Gandara DR, et al. The tissue is the issue: personalized medicine for non-small cell lung cancer. Clin Cancer Res. 2010;16(20):4909–4911.
   PubMed Web of Science ®Google Scholar
• Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010;34(12):1805–1811.
   PubMed Web of Science ®Google Scholar
• Kossakowski CA, Morresi-Hauf A, Schnabel PA, et al. Preparation of cell blocks for lung cancer diagnosis and prediction: protocol and experience of a high-volume center. Respiration. 2014;87(5):432–438.
   PubMed Web of Science ®Google Scholar
• Warth A, Muley T, Herpel E, et al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology. 2012;61(6):1017–1025.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Rossi G, Bianchi F, et al. Immunhistochemistry by means of widely agreed-upon markers (Cytokeratins 5/6 and 7, p63, Thyroid Transcription Factor-1, and Vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol. 2011;6:1039–1049.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Fabbri A, Tamborini E, et al. Challenging lung carcinoma with coexistent DeltaNp63/p40 and thyroid transcription factor-1 labeling within the same individual tumor cells. J Thorac Oncol. 2015;10(10):1500–1502.
   PubMed Web of Science ®Google Scholar
• Schnabel PA, Smit E, Carpeno Jde C, et al. Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: baseline results of an observational study (FRAME). Lung Cancer. 2012;78(3):263–269.
   PubMed Web of Science ®Google Scholar
• Gridelli C, Ardizzoni A, Douillard JY, et al. Recent issues in first-line treatment of advanced non-small-cell lung cancer: results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer. 2010;68(3):319–331.
   PubMed Web of Science ®Google Scholar
• Kerr KM. Personalized medicine for lung cancer: new challenges for pathology. Histopathology. 2012;60(4):531–546.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693–1703.
   PubMed Web of Science ®Google Scholar
• Chan SS, Kyba M. What is a master regulator? J Stem Cell Res Ther. 2013;3:e114. doi:10.4172/2157-7633.1000e114.
   PubMedGoogle Scholar
• Bari MF, Brown H, Nicholson AG, et al. BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas. Histopathology. 2014;64(4):547–556.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Fabbri A, Cossa M, et al. What clinicians are asking pathologists when dealing with lung neuroendocrine neoplasms? Semin Diagn Pathol. 2015;32(6):469–479.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Pasini F, Olsen Stenholm C et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol. 2002;198(1):100–109.
   PubMed Web of Science ®Google Scholar
• Agoff S, Lamps L, Philip A, et al. Thyroid transcription factor-1 is expressed in extrapulmonary small cell carcinomas but not in other extrapulmonary neuroendocrine tumors. Mod Pathol. 2000;13(3):238–242.
   PubMed Web of Science ®Google Scholar
• Kaufmann O, Dietel M. Expression of thyroid transcription factor-1 in pulmonary and extrapulmonary small cell carcinomas and other neuroendocrine carcinomas of various primary sites. Histopathology. 2000;36(5):415–420.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Papotti M, Rindi G, et al. Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors. Endocr Pathol. 2014;25:151–164.
   PubMed Web of Science ®Google Scholar
• Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med. 2010;134(11):1628–1638.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Sonzogni A, Galetta D, et al. Combined small-cell carcinoma of the lung with quadripartite differentiation of epithelial, neuroendocrine, skeletal muscle, and myofibroblastic type. Virchows Arch. 2011;458(4):497–503.
   PubMed Web of Science ®Google Scholar
• Travis WD, Rekhtman N, Riley GJ, et al. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol. 2010;5(4):411–414.
   PubMed Web of Science ®Google Scholar
• Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing. Semin Respir Crit Care Med. 2011;32(1):22–31.
   PubMed Web of Science ®Google Scholar
• Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol. 2010;5(4):442–447.
   PubMed Web of Science ®Google Scholar
• Thunnissen E, Kerr KM, Herth FJ, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer. 2012;76(1):1–18.
   PubMed Web of Science ®Google Scholar
• Ziegler A, Koch A, Krockenberger K, et al. Personalized medicine using DNA biomarkers: a review. Hum Genet. 2012;131(10):1627–1638.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Haspinger ER, Bimbatti M, et al. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases. Int J Surg Pathol. 2014;22(2):136–148.
   PubMed Web of Science ®Google Scholar
• Righi L, Vavala T, Rapa I, et al. Impact of non-small-cell lung cancer-not otherwise specified immunophenotyping on treatment outcome. J Thorac Oncol. 2014;9(10):1540–1546.
   PubMed Web of Science ®Google Scholar
• Rossi G, Pelosi G, Barbareschi M, et al. Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice. Int J Surg Pathol. 2013;21(4):326–336.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Sonzogni A, De Pas T et al. Review article: pulmonary sarcomatoid carcinomas: a practical overview. Int J Surg Pathol. 2010;18(2):103–120.
   PubMed Web of Science ®Google Scholar
• Matoso A, Singh K, Jacob R, et al. Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol. 2010;18(2):142–149.
   PubMedGoogle Scholar
• Travis WD, Brambilla E, Nicholson AG. Testing for neuroendocrine immunohistochemical markers should not be performed in poorly differentiated NSCCs in the absence of neuroendocrine morphologic features according to the 2015 WHO classification. J Thorac Oncol. 2016;11(2):e26–e27.
   PubMed Web of Science ®Google Scholar
• Derks JL, Speel EJ, Thunnissen E, et al. Neuroendocrine cancer of the lung: a diagnostic puzzle. J Thorac Oncol. 2016;11(3):e35–e38.
   PubMed Web of Science ®Google Scholar
• Gottschling S, Jensen K, Herth FJ, et al. Lack of prognostic significance of neuroendocrine differentiation and stem cell antigen co-expression in resected early-stage non-small cell lung cancer. Anticancer Res. 2013;33(3):981–990.
   PubMed Web of Science ®Google Scholar
• Howe MC, Chapman A, Kerr K, et al. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy. Histopathology. 2005;46(2):195–201.
   PubMed Web of Science ®Google Scholar
• Ionescu DN, Treaba D, Gilks CB, et al. Nonsmall cell lung carcinoma with neuroendocrine differentiation–an entity of no clinical or prognostic significance. Am J Surg Pathol. 2007;31(1):26–32.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Pasini F, Sonzogni A, et al. Prognostic implications of neuroendocrine differentiation and hormone production in patients with Stage I nonsmall cell lung carcinoma. Cancer. 2003;97(10):2487–2497.
   PubMed Web of Science ®Google Scholar
• Petrović M, Baskić D, Bankovic D, et al. Neuroendocrine differentiation as an indicator of chemosensitivity and prognosis in nonsmall cell lung cancer. Biomarkers. 2011;16(4):311–320.
   PubMed Web of Science ®Google Scholar
• Segawa Y, Takata S, Fujii M, et al. Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications. J Cancer Res Clin Oncol. 2009;135(8):1055–1059.
   PubMed Web of Science ®Google Scholar
• Sterlacci W, Fiegl M, Hilbe W, et al. Clinical relevance of neuroendocrine differentiation in non-small cell lung cancer assessed by immunohistochemistry: a retrospective study on 405 surgically resected cases. Virchows Arch. 2009;455(2):125–132.
   PubMed Web of Science ®Google Scholar
• Derks JL, Speel EJ, Dingemans AM. An unmet need in the WHO 2015 biopsy classification: poorly differentiated NSCCs with positive neuroendocrine markers. J Thorac Oncol. 2016;11(2):e25–e26.
   PubMedGoogle Scholar
• Petersen I, Warth A. Lung cancer: developments, concepts, and specific aspects of the new WHO classification. J Cancer Res Clin Oncol. 2016;142(5):895–904.
   PubMed Web of Science ®Google Scholar
• Chang YL, Wu CT, Shih JY, et al. EGFR and p53 status of pulmonary pleomorphic carcinoma: implications for EGFR tyrosine kinase inhibitors therapy of an aggressive lung malignancy. Ann Surg Oncol. 2011;18(10):2952–2960.
   Web of Science ®Google Scholar
• Fallet V, Saffroy R, Girard N, et al. High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta Panel: exploring therapeutic targets. Ann Oncol. 2015;26(8):1748–1753.
   PubMed Web of Science ®Google Scholar
• Forest F, Yvorel V, Karpathiou G, et al. Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies. Hum Pathol. 2016;49:99–106.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim Y, Sun JM, et al. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. J Cancer Res Clin Oncol. 2011;137(8):1203–1211.
   PubMed Web of Science ®Google Scholar
• Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2016;34(8):794–802.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Gasparini P, Cavazza A, et al. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer. 2012;77(3):507–514.
   PubMed Web of Science ®Google Scholar
• Tamura Y, Fujiwara Y, Yamamoto N, et al. Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. BMC Res Notes. 2015;8:800.
   PubMedGoogle Scholar
• Terra SB, Jang JS, Bi L, et al. Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases. Mod Pathol. 2016;29(8):824–831.
   PubMed Web of Science ®Google Scholar
• Lococo F, Gandolfi G, Rossi G, et al. Deep sequencing analysis reveals that kras mutation is a marker of poor prognosis in patients with pulmonary sarcomatoid carcinoma. J Thorac Oncol. 2016;11(8):1282–1292.
   PubMed Web of Science ®Google Scholar
• Weingertner N, Meyer N, Voegeli AC, et al. Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification. Pathology. 2015;47(4):320–328.
   PubMed Web of Science ®Google Scholar
• Lee C, Usenko D, Frampton GM, et al. MET 14 Deletion in sarcomatoid non-small-cell lung cancer detected by next-generation sequencing and successfully treated with a MET inhibitor. J Thorac Oncol. 2015;10(12):e113–e114.
   PubMed Web of Science ®Google Scholar
• Tsuta K, Kalhor N, Wistuba II, et al. Clinicopathological and immunohistochemical analysis of spindle-cell carcinoid tumour of the lung. Histopathology. 2011;59(3):526–536.
   PubMed Web of Science ®Google Scholar
• Tsuta K, Kozu Y, Mimae T, et al. c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol. 2012;7(2):331–339.
   PubMed Web of Science ®Google Scholar
• Ou SH, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 2011;6(5):942–946.
   PubMed Web of Science ®Google Scholar
• van der Wekken AJ, Saber A, Hiltermann TJ, et al. Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature. Crit Rev Oncol Hematol. 2016;100:107–116.
   PubMed Web of Science ®Google Scholar
• Ivaska J. Vimentin: central hub in EMT induction? Small Gtpases. 2011;2(1):51–53.
   PubMedGoogle Scholar
• Pelosi G, Melotti F, Cavazza A, et al. A modified vimentin histological score helps recognize pulmonary sarcomatoid carcinoma in small biopsy samples. Anticancer Res. 2012;32(4):1463–1473.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Fraggetta F, Nappi O, et al. Pleomorphic carcinomas of the lung show a selective distribution of gene products involved in cell differentiation, cell cycle control, tumor growth and tumor cell motility: a clinicopathological and immunohistochemical study of 31 cases. Am J Surg Pathol. 2003;27:1203–1215.
   PubMed Web of Science ®Google Scholar
• Zachara-Szczakowski S, Verdun T, Churg A. Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers. Hum Pathol. 2015;46(5):776–782.
   PubMed Web of Science ®Google Scholar
• Kerr KM, Tsao MS, Nicholson AG, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? J Thorac Oncol. 2015;10(7):985–989.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189–1197.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385–2394.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Solomon B. Targeting anaplastic lymphoma kinase in lung cancer. Clin Cancer Res. 2011;17(8):2081–2086.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Sonobe M, Kobayashi M, et al. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene. Ann Surg Oncol. 2010;17(3):889–897.
   PubMed Web of Science ®Google Scholar
• Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res. 2009;15(16):5216–5223.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 2011;35(8):1226–1234.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Tsuta K, Watanabe S, et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer. 2011;72(3):309–315.
   PubMed Web of Science ®Google Scholar
• Cha YJ, Han J, Hwang SH, et al. ALK-rearranged adenocarcinoma with extensive mucin production can mimic mucinous adenocarcinoma: clinicopathological analysis and comprehensive histological comparison with KRAS-mutated mucinous adenocarcinoma. Pathology. 2016;48(4):325–329.
   PubMed Web of Science ®Google Scholar
• Martelli MP, Sozzi G, Hernandez L, et al. EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues. Am J Pathol. 2009;174(2):661–670.
   PubMed Web of Science ®Google Scholar
• Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas. Hum Pathol. 2009;40(8):1152–1158.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Perrone F, Tamborini E, et al. Doing more with less: fluorescence in situ hybridization and gene sequencing assays can be reliably performed on archival stained tumor tissue sections. Virchows Arch. 2016;468(4):451–461.
   PubMed Web of Science ®Google Scholar
• Conklin CM, Craddock KJ, Have C, et al. Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent. J Thorac Oncol. 2013;8(1):45–51.
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137(6):828–860.
   PubMed Web of Science ®Google Scholar
• Ali SM, Hensing T, Schrock AB, et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. Oncologist. 2016;21(6):762–770.
   PubMed Web of Science ®Google Scholar
• Gruber K, Kohlhäufl M, Friedel G, et al. A novel, highly sensitive ALK antibody 1A4 facilitates effective screening for ALK rearrangements in lung adenocarcinomas by standard immunohistochemistry. J Thorac Oncol. 2015;10(4):713–716.
   PubMed Web of Science ®Google Scholar
• Shen Q, Wang X, Yu B, et al. Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC). Lung Cancer. 2015;90(3):492–498.
   PubMed Web of Science ®Google Scholar
• Ma D, Wang Z, Yang L, et al. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative. Oncotarget. 2016. doi:10.18632/oncotarget.10124.
   Web of Science ®Google Scholar
• Wang Q, Zhao L, Yang X, et al. Antibody 1A4 with routine immunohistochemistry demonstrates high sensitivity for ALK rearrangement screening of Chinese lung adenocarcinoma patients: A single-center large-scale study. Lung Cancer. 2016;95:39–43.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Di Lorito A, Pace MV, et al. ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol. 2016;11(4):487–495.
   PubMed Web of Science ®Google Scholar
• Marchetti A, Barberis M, Papotti M, et al. ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme. J Thorac Oncol. 2014;9(10):1470–1476.
   PubMed Web of Science ®Google Scholar
• Mattsson JSM, Brunnström H, Jabs V, et al. Inconsistent results in the analysis of ALK rearrangements in non-small cell lung cancer. BMC Cancer. 2016;16:603.
   PubMed Web of Science ®Google Scholar
• Lu S, Zhang J, Ye M, et al. Economic analysis of ALK testing and crizotinib therapy for advanced non-small-cell lung cancer. Pharmacogenomics. 2016;17(9):985–994.
   PubMed Web of Science ®Google Scholar
• Viola P, Maurya M, Croud J, et al. A validation study for the use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer. J Thorac Oncol. 2016;11(7):1029–1039.
   PubMed Web of Science ®Google Scholar
• Routhier CA, Mochel MC, Lynch K, et al. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol. 2013;44(11):2563–2570.
   PubMed Web of Science ®Google Scholar
• Brevet M, Arcila M, Ladanyi M. Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. J Mol Diagn. 2010;12(2):169–176.
   PubMed Web of Science ®Google Scholar
• Hasanovic A, Ang D, Moreira AL, et al. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma. Lung Cancer. 2012;77(2):299–305.
   PubMed Web of Science ®Google Scholar
• Kawahara A, Taira T, Azuma K, et al. A diagnostic algorithm using EGFR mutation-specific antibodies for rapid response EGFR-TKI treatment in patients with non-small cell lung cancer. Lung Cancer. 2012;78(1):39–44.
   PubMed Web of Science ®Google Scholar
• Kitamura A, Hosoda W, Sasaki E, et al. Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer. Clin Cancer Res. 2010;16(13):3349–3355.
   PubMed Web of Science ®Google Scholar
• Rossi G, Ragazzi M, Tamagnini I, et al. Does immunohistochemistry represent a robust alternative technique in determining drugable predictive gene alterations in non-small cell lung cancer? Curr Drug Targets. 2015. [Epub ahead of print].
   Google Scholar
• Agarwal A, Ressler D, Snyder G. The current and future state of companion diagnostics. Pharmgenomics Pers Med. 2015;8:99–110.
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S, Katzenstein AL. Comparison of monoclonal napsin A, polyclonal napsin A, and TTF-1 for determining lung origin in metastatic adenocarcinomas. Am J Clin Pathol. 2012;138(5):703–711.
   PubMed Web of Science ®Google Scholar
• Minoo P, Hamdan H, Bu D, et al. TTF-1 regulates lung epithelial morphogenesis. Dev Biol. 1995;172:694–698.
   PubMed Web of Science ®Google Scholar
• Stahlman M, Gray M, Whitsett J. Expression of thyroid transcriptional factor-1 (TTF-1) in fetal and neonatal human lung. J Histochem Cytochem. 1996;44:673–678.
   PubMed Web of Science ®Google Scholar
• Zhang L, Whitsett J, Stripp B. Regulation of Clara cell secretory protein gene transcription by thyroid transcription factor-1. Biochim Biophys Acta. 1997;1350:359–367.
   PubMed Web of Science ®Google Scholar
• Rossi G, Cavazza A, Sturm N, et al. Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. Am J Surg Pathol. 2003;27:311–324.
   PubMed Web of Science ®Google Scholar
• Yatabe Y. EGFR mutations and the terminal respiratory unit. Cancer Metastasis Rev. 2010;29(1):23–36.
   PubMed Web of Science ®Google Scholar
• Falk N, Weissferdt A, Kalhor N, et al. Primary pulmonary salivary gland-type tumors: a review and update. Adv Anat Pathol. 2016;23(1):13–23.
   PubMed Web of Science ®Google Scholar
• Stathis A, Zucca E, Bekradda M, et al. Clinical response of carcinomas harboring the BRD4-NUT oncoprotein to the targeted bromodomain inhibitor OTX015/MK-8628. Cancer Discov. 2016;6(5):492–500.
   PubMed Web of Science ®Google Scholar
• French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol. 2012;7:247–265.
   PubMed Web of Science ®Google Scholar
• Sholl LM, Nishino M, Pokharel S, et al. Primary pulmonary NUT midline carcinoma: clinical, radiographic, and pathologic characterizations. J Thorac Oncol. 2015;10(6):951–959.
   PubMed Web of Science ®Google Scholar
• Tanaka M, Kato K, Gomi K, et al. NUT midline carcinoma: report of 2 cases suggestive of pulmonary origin. Am J Surg Pathol. 2012;36(3):381–388.
   PubMed Web of Science ®Google Scholar
• Haack H, Johnson LA, Fry CJ, et al. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol. 2009;33(7):984–991.
   PubMed Web of Science ®Google Scholar
• French CA. NUT midline carcinoma. Cancer Genet Cytogenet. 2010;203(1):16–20.
   PubMedGoogle Scholar
• Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A. 2000;97(10):5462–5467.
   PubMed Web of Science ®Google Scholar
• Okuyama R, Ogawa E, Nagoshi H, et al. p53 homologue, p51/p63, maintains the immaturity of keratinocyte stem cells by inhibiting Notch1 activity. Oncogene. 2007;26(31):4478–4488.
   PubMed Web of Science ®Google Scholar
• Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2(3):305–316.
   PubMed Web of Science ®Google Scholar
• Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398(6729):714–718.
   PubMed Web of Science ®Google Scholar
• Yang A, Zhu Z, Kettenbach A, et al. Genome-wide mapping indicates that p73 and p63 co-occupy target sites and have similar dna-binding profiles in vivo. PLoS One. 2010;5(7):e11572.
   PubMed Web of Science ®Google Scholar
• Yang X, Lu H, Yan B, et al. DeltaNp63 versatilely regulates a Broad NF-kappaB gene program and promotes squamous epithelial proliferation, migration, and inflammation. Cancer Res. 2011;71(10):3688–3700.
   PubMed Web of Science ®Google Scholar
• Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol. 2011;35(6):853–860.
   PubMed Web of Science ®Google Scholar
• Sethi I, Romano RA, Gluck C, et al. A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues. BMC Genomics. 2015;16:584.
   PubMed Web of Science ®Google Scholar
• Nekulova M, Holcakova J, Coates P, et al. The role of p63 in cancer, stem cells and cancer stem cells. Cell Mol Biol Lett. 2011;16(2):296–327.
   PubMed Web of Science ®Google Scholar
• King KE, Ponnamperuma RM, Gerdes MJ, et al. Unique domain functions of p63 isotypes that differentially regulate distinct aspects of epidermal homeostasis. Carcinogenesis. 2006;27(1):53–63.
   PubMed Web of Science ®Google Scholar
• Romano RA, Ortt K, Birkaya B, et al. An active role of the DeltaN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS One. 2009;4(5):e5623.
   PubMed Web of Science ®Google Scholar
• Romano RA, Smalley K, Magraw C, et al. DeltaNp63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Development. 2012;139(4):772–782.
   PubMed Web of Science ®Google Scholar
• Karni-Schmidt O, Castillo-Martin M, Shen TH, et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol. 2011;178(3):1350–1360.
   PubMed Web of Science ®Google Scholar
• Boldrup L, Coates PJ, Gu X, et al. DeltaNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of Cox-2 as a novel p63 target. J Pathol. 2009;218(4):428–436.
   PubMed Web of Science ®Google Scholar
• Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res. 2012;18(4):1167–1176.
   PubMed Web of Science ®Google Scholar
• Saintigny P, El-Naggar AK, Papadimitrakopoulou V, et al. DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia. Clin Cancer Res. 2009;15(19):6284–6291.
   PubMed Web of Science ®Google Scholar
• Stelow EB, Bellizzi AM, Taneja K, et al. NUT rearrangement in undifferentiated carcinomas of the upper aerodigestive tract. Am J Surg Pathol. 2008;32(6):828–834.
   PubMed Web of Science ®Google Scholar
• Kadota K, Nitadori J, Rekhtman N, et al. Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis. Am J Surg Pathol. 2015;39(9):1170–1180.
   PubMed Web of Science ®Google Scholar
• Uramoto H, Yamada S, Hanagiri T. Immunohistochemical staining with deltaNp63 is useful for distinguishing the squamous cell component of adenosquamous cell carcinoma of the lung. Anticancer Res. 2010;30(11):4717–4720.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Sonzogni A, Papotti M, et al. Different prevalence of transactivating (TA) p63 and non-TAp63 isoforms in pulmonary adenocarcinomas: a useful diagnostic tool. Mod Pathol. 2010;23:396A–415A.
   Web of Science ®Google Scholar
• Sharma R, Wang Y, Chen L, et al. Utility of a novel triple marker (Combination of TTF-1, Napsin-A and P40) in the Subclassification of non-small cell lung carcinomas using fine-needle aspiration cases. Hum Pathol. 2016;54:8–16.
   Web of Science ®Google Scholar
• Rekhtman N, Pietanza MC, Hellmann MD, et al. Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res. 2016;15;22(14):3618–3629.
   Web of Science ®Google Scholar
• Turner BM, Cagle PT, Sainz IM, et al. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med. 2012;136(2):163–171.
   PubMed Web of Science ®Google Scholar
• Cooper JB. Aspartic proteinases in disease: a structural perspective. Curr Drug Targets. 2002;3(2):155–173.
   PubMed Web of Science ®Google Scholar
• Ao MH, Zhang H, Sakowski L, et al. The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer. Hum Pathol. 2014;45(5):926–934.
   PubMed Web of Science ®Google Scholar
• Noh S, Shim H. Optimal combination of immunohistochemical markers for subclassification of non-small cell lung carcinomas: a tissue microarray study of poorly differentiated areas. Lung Cancer. 2012;76(1):51–55.
   PubMed Web of Science ®Google Scholar
• Tatsumori T, Tsuta K, Masai K, et al. p40 is the best marker for diagnosing pulmonary squamous cell carcinoma: comparison with p63, cytokeratin 5/6, desmocollin-3, and sox2. Appl Immunohistochem Mol Morphol. 2014;22(5):377–382.
   PubMedGoogle Scholar
• Masai K, Tsuta K, Kawago M, et al. Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol. 2013;21(4):292–297.
   PubMedGoogle Scholar
• Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41(11):1238–1242.
   PubMed Web of Science ®Google Scholar
• Hussenet T, du Manoir S. SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis. Cell Cycle. 2010;9(8):1480–1486.
   PubMed Web of Science ®Google Scholar
• Rossi G, Marchioni A, Milani M, et al. TTF-1, cytokeratin 7, 34betaE12, and CD56/NCAM immunostaining in the subclassification of large cell carcinomas of the lung. Am J Clin Pathol. 2004;122(6):884–893.
   PubMed Web of Science ®Google Scholar
• Butnor KJ, Burchette JL. p40 (DeltaNp63) and keratin 34betaE12 provide greater diagnostic accuracy than p63 in the evaluation of small cell lung carcinoma in small biopsy samples. Hum Pathol. 2013;44(8):1479–1486.
   PubMed Web of Science ®Google Scholar
• Ordóñez NG. A word of caution regarding napsin A expression in squamous cell carcinomas of the lung. Am J Surg Pathol. 2012;36(3):396–401.
   PubMed Web of Science ®Google Scholar
• Micke P, Mattsson JS, Djureinovic D, et al. The impact of the fourth edition of the WHO classification of lung tumours on histological classification of resected pulmonary NSCCs. J Thorac Oncol. 2016;11(6):862–872.
   PubMed Web of Science ®Google Scholar
• Tran L, Mattsson JS, Nodin B, et al. Various antibody clones of napsin A, thyroid transcription factor 1, and p40 and comparisons with cytokeratin 5 and p63 in histopathologic diagnostics of non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol. 2015. [Epub ahead of print].
   PubMedGoogle Scholar
• Kashima K, Hashimoto H, Nishida H, et al. Significant expression of thyroid transcription factor-1 in pulmonary squamous cell carcinoma detected by SPT24 monoclonal antibody and CSA-II system. Appl Immunohistochem Mol Morphol. 2014;22(2):119–124.
   PubMedGoogle Scholar
• La Rosa S, Chiaravalli AM, Placidi C, et al. TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch. 2010;457(4):497–507.
   PubMed Web of Science ®Google Scholar
• Klebe S, Swalling A, Jonavicius L, et al. An immunohistochemical comparison of two TTF-1 monoclonal antibodies in atypical squamous lesions and sarcomatoid carcinoma of the lung, and pleural malignant mesothelioma. J Clin Pathol. 2016;69(2):136–141.
   PubMed Web of Science ®Google Scholar
• Ordóñez NG. Thyroid transcription factor-1 is not expressed in squamous cell carcinomas of the lung: an immunohistochemical study with review of the literature. Appl Immunohistochem Mol Morphol. 2012;20(6):525–530.
   PubMedGoogle Scholar
• Niu HL, Pasha TL, Pawel BR, et al. Thyroid transcription factor-1 expression in normal gynecologic tissues and its potential significance. Int J Gynecol Pathol. 2009;28(4):301–307.
   PubMed Web of Science ®Google Scholar
• Robens J, Goldstein L, Gown AM, et al. Thyroid transcription factor-1 expression in breast carcinomas. Am J Surg Pathol. 2010;34(12):1881–1885.
   PubMed Web of Science ®Google Scholar
• Siami K, McCluggage WG, Ordonez NG, et al. Thyroid transcription factor-1 expression in endometrial and endocervical adenocarcinomas. Am J Surg Pathol. 2007;31(11):1759–1763.
   PubMed Web of Science ®Google Scholar
• Klingen TA, Chen Y, Suhrke P, et al. Expression of thyroid transcription factor-1 is associated with a basal-like phenotype in breast carcinomas. Diagn Pathol. 2013;8:80.
   PubMed Web of Science ®Google Scholar
• Sakurai A, Sakai Y, Yatabe Y. Thyroid transcription factor-1 expression in rare cases of mammary ductal carcinoma. Histopathology. 2011;59(1):145–148.
   PubMed Web of Science ®Google Scholar
• Kubba LA, McCluggage WG, Liu J, et al. Thyroid transcription factor-1 expression in ovarian epithelial neoplasms. Mod Pathol. 2008;21(4):485–490.
   PubMed Web of Science ®Google Scholar
• Ordóñez NG. Value of thyroid transcription factor-1 immunostaining in tumor diagnosis: a review and update. Appl Immunohistochem Mol Morphol. 2012;20(5):429–444.
   PubMedGoogle Scholar
• Rekhtman N, Kazi S. Nonspecific reactivity of polyclonal napsin a antibody in mucinous adenocarcinomas of various sites: a word of caution. Arch Pathol Lab Med. 2015;139(4):434–436.
   PubMed Web of Science ®Google Scholar
• Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol. 2010;41(1):20–25.
   PubMed Web of Science ®Google Scholar
• Rossi G, Cavazza A, Righi L, et al. Napsin-A, TTF-1, EGFR, and ALK status determination in lung primary and metastatic mucin-producing adenocarcinomas. Int J Surg Pathol. 2014;22(5):401–407.
   PubMed Web of Science ®Google Scholar
• Kadivar M, Boozari B. Applications and limitations of immunohistochemical expression of “Napsin-A” in distinguishing lung adenocarcinoma from adenocarcinomas of other organs. Appl Immunohistochem Mol Morphol. 2013;21(3):191–195.
   PubMedGoogle Scholar
• Vitkovski T, Chaudhary S, Sison C, et al. Aberrant expression of napsin A in breast carcinoma with apocrine features. Int J Surg Pathol. 2016;24(5):377–381.
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Nakatani Y, Fugo K, et al. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium. Hum Pathol. 2015;46(7):957–962.
   PubMed Web of Science ®Google Scholar
• Heymann JJ, Hoda RS, Scognamiglio T. Polyclonal napsin A expression: a potential diagnostic pitfall in distinguishing primary from metastatic mucinous tumors in the lung. Arch Pathol Lab Med. 2014;138(8):1067–1071.
   PubMed Web of Science ®Google Scholar
• HooKim K, Chaudoir CS, Chaudhery SI, et al. The use of a novel immunohistochemical triple cocktail in the subclassification of resected non-small cell lung carcinomas: a comparative study with morphology and traditional immunohistochemistry. Appl Immunohistochem Mol Morphol. 2016 [Epub ahead of print].
   PubMedGoogle Scholar
• Marci V, Volante M, Cappia S, et al. Basaloid adenocarcinoma. A new variant of pulmonary adenocarcinoma. Virchows Arch. 2007;451(3):729–736.
   PubMed Web of Science ®Google Scholar
• Molina JR, Aubry MC, Lewis JE, et al. Primary salivary gland-type lung cancer: spectrum of clinical presentation, histopathologic and prognostic factors. Cancer. 2007;110(10):2253–2259.
   PubMed Web of Science ®Google Scholar
• Pelosi G, Petrella F, Sandri MT, et al. A primary pure yolk sac tumor of the lung exhibiting CDX-2 immunoreactivity and increased serum levels of alkaline phosphatase intestinal isoenzyme. Int J Surg Pathol. 2006;14(3):247–251.
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Franklin WA, Nicholson AG, et al. The IASLC lung cancer staging project: background data and proposed criteria to distinguish separate primary lung cancers from metastatic foci in patients with two lung tumors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(5):651–665.
   PubMed Web of Science ®Google Scholar
• Lantuejoul S, Moro D, Michalides RJ, et al. Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am J Surg Pathol. 1998;22(10):1267–1276.
   PubMed Web of Science ®Google Scholar
• Lantuejoul S, Laverriere MH, Sturm N, et al. NCAM (neural cell adhesion molecules) expression in malignant mesotheliomas. Hum Pathol. 2000;31(4):415–421.
   PubMed Web of Science ®Google Scholar
• Sartelet H, Lantuejoul S, Armari-Alla C, et al. Solid alveolar rhabdomyosarcoma of the thorax in a child. Histopathology. 1998;32(2):165–171.
   PubMed Web of Science ®Google Scholar
• Hartel PH, Fanburg-Smith JC, Frazier AA, et al. Primary pulmonary and mediastinal synovial sarcoma: a clinicopathologic study of 60 cases and comparison with five prior series. Mod Pathol. 2007;20(7):760–769.
   PubMed Web of Science ®Google Scholar
• Lucas DR, Pass HI, Madan SK, et al. Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study. Histopathology. 2003;42(3):270–279.
   PubMed Web of Science ®Google Scholar
• Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013;137(5):647–667.
   PubMed Web of Science ®Google Scholar
• Travis WD. Sarcomatoid neoplasms of the lung and pleura. Arch Pathol Lab Med. 2010;134(11):1645–1658.
   PubMed Web of Science ®Google Scholar
• Rdzanek M, Fresco R, Pass HI, et al. Spindle cell tumors of the pleura: differential diagnosis. Semin Diagn Pathol. 2006;23(1):44–55.
   PubMed Web of Science ®Google Scholar
• Keel SB, Bacha E, Mark EJ, et al. Primary pulmonary sarcoma: a clinicopathologic study of 26 cases. Mod Pathol. 1999;12(12):1124–1131.
   PubMed Web of Science ®Google Scholar
• Bégueret H, Galateau-Salle F, Guillou L, et al. Primary intrathoracic synovial sarcoma: a clinicopathologic study of 40 t(X;18)-positive cases from the French Sarcoma Group and the Mesopath Group. Am J Surg Pathol. 2005;29(3):339–346.
   PubMed Web of Science ®Google Scholar